RFA
OCRX

Reilly Financial Advisors’s Ocera Therapeutics, Inc. OCRX Stock Holding History

Reilly Financial Advisors’s Portfolio OCRX Stock Details OCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-200
Closed – – 983
2016
Q4 		$0 Buy
+200
New +$467 ﹤0.01% 951

Other funds holding OCRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Reilly Financial Advisors's OCRX Position: Q1 2017 in Review

Reilly Financial Advisors sold out of Ocera Therapeutics, Inc. (OCRX) in Q1 2017, closing a stake of 200 shares.

Reilly Financial Advisors first reported a position in OCRX in Q4 2016 and held it in 1 quarter. The position peaked at $0 in Q4 2016. 26 funds tracked by Wall St. Rank hold OCRX as of Q1 2017.

  • Reilly Financial Advisors reported no remaining Ocera Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Reilly Financial Advisors sold 200 Ocera Therapeutics, Inc. shares in Q1 2017.
  • Reilly Financial Advisors first reported a position in Ocera Therapeutics, Inc. in Q4 2016 and held it in 1 quarter.
  • Reilly Financial Advisors's Ocera Therapeutics, Inc. position peaked at $0 in Q4 2016.
  • 26 funds tracked by Wall St. Rank held Ocera Therapeutics, Inc. as of Q1 2017.

Based on Reilly Financial Advisors's 13F filing for Q1 2017, filed 18 Apr 2017.